The difference between Isri and pirfenidone

Isri and pirfenidone (Pirfenidone) are actually different translated names of the same drug, mainly used to treat idiopathic pulmonary fibrosis (IPF). The mechanism of action, clinical application and side effects of this drug are relatively clear, so Asri is the trade name of pirfenidone sold in China, and may also be called pirfenidone in some places.

Pirfenidone, as an anti-fibrotic drug, can effectively slow down the decline of lung function and improve the quality of life in patients with idiopathic pulmonary fibrosis. Its mechanism of action involves multiple biological pathways, including inhibiting fibrosis-related cytokines and regulating the activity of fibroblasts. Specifically, pirfenidone reduces the fibrosis process of lung tissue by inhibiting the transforming growth factor β (TGF-β) signaling pathway and reducing collagen synthesis.

In terms of clinical application, pirfenidone is usually administered in oral form, and patients need to follow the doctor's medication regimen. Typically, treatment is started at a lower dose to reduce the risk of side effects and is gradually increased to the recommended therapeutic dose. Studies have shown that pirfenidone has a significant effect in slowing the progression of the disease and can also reduce the hospitalization and mortality rates associated with IPF.

Although pirfenidone has shown good efficacy in the treatment of idiopathic pulmonary fibrosis, some side effects may occur during its use. Common adverse reactions include gastrointestinal discomfort, such as nausea, diarrhea, etc., and some patients also experience rash or abnormal liver function. Therefore, doctors usually monitor the patient's specific situation and adjust the dose or take other measures if necessary.

In addition, the development and marketing of pirfenidone marks the importance of idiopathic pulmonary fibrosis, a rare and serious disease. It provides patients with new treatment options and improves their survival and quality of life. Internationally, Asri has been approved by many countries and regions and has become one of the important drugs for the treatment of IPF.